Once-weekly insulin approval adds another diabetes product but does not change LLY's core valuation debate.

What happened

Eli Lilly received FDA approval for a once-weekly insulin, but the stock is already up 60% and knocking on $1,200, near the base-case implied value of $1,210. The DeepValue report shows that the company's revenue is 65% concentrated in Mounjaro and Zepbound, with a 13% consolidated price headwind, and the newly approved insulin was already noted as a pipeline milestone (CHMP positive opinion for insulin efsitora alfa). The approval is a positive for the diabetes portfolio but does not address the central questions of net pricing stabilization and retail adoption of oral Foundayo. The valuation at 39.8x earnings leaves little room for operational slippage, and the market remains crowded around obesity leadership assumptions. The stock's move toward $1,200 is consistent with the base scenario, but the report recommends waiting for evidence that broader access is accretive, not just available.

Implication

Investors should treat the once-weekly insulin approval as a incremental portfolio addition rather than a catalyst for re-rating, as it does not alter the core economics of the obesity franchise. The key variables to watch remain U.S. net-price stabilization for Mounjaro and Zepbound, measurable Medicare Bridge uptake, and Foundayo's transition from LillyDirect and telehealth to mainstream retail. At $1,187, the stock already prices in sustained obesity leadership and oral expansion, offering limited upside without confirmation that volume growth can continue to outpace price erosion. The DeepValue report suggests an attractive entry near $1,050 and trimming above $1,300, so current levels warrant patience rather than new positions. A disciplined approach would wait for the next two quarterly filings to provide harder data on access and pricing before committing additional capital.

Thesis delta

No material shift. The once-weekly insulin approval was already anticipated as a pipeline milestone (CHMP positive opinion noted in the 10-Q), and the core thesis remains centered on incretin pricing, Medicare Bridge uptake, and Foundayo retail adoption. The news does not change the risk-reward at current valuation, which still requires volume growth to absorb price concessions.